These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38436915)

  • 1. The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre "Real-Life" Cohort Study.
    Ruscitti P; Cataldi G; Gentile M; Dionisi A; Volpe P; Finucci A; Verardi L; Di Muzio C; Italiano N; Celletti E; Di Penta M; Di Cola I; Marrelli A; Alfonsi A; Delle Monache F; Cipollone F; Gabini M; Cipriani P
    Rheumatol Ther; 2024 Jun; 11(3):539-551. PubMed ID: 38436915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort.
    Ruscitti P; Pantano I; Perrotta FM; Celletti E; Volpe P; Ciliento MS; Marino V; Raimondi M; Gaggiano E; Mauro D; Cataldi G; Italiano N; Di Muzio C; Navarini L; Zicolella R; Gabini M; Cipollone F; Lubrano E; Giacomelli R; Ciccia F; Cipriani P
    Clin Exp Rheumatol; 2024 Jan; 42(1):69-76. PubMed ID: 37497733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort.
    Ramonda R; Lorenzin M; Chimenti MS; Atzeni F; Semeraro A; D'Angelo S; Selmi C; Ortolan A; Marchesoni A; Manara M; Luchetti Gentiloni MM; Santo L; Salvarani C; Cauli A; Rossini M; Amato G; Cozzi G; Scagnellato L; Ferraioli M; Carriero A; Fracassi E; Giorgio F; Doria A; Foti R; Carletto A;
    Arthritis Res Ther; 2024 Sep; 26(1):172. PubMed ID: 39342310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
    Mease PJ; Gottlieb AB; Ogdie A; McInnes IB; Chakravarty SD; Rampakakis E; Kollmeier A; Xu XL; Shawi M; Lavie F; Kishimoto M; Rahman P
    Clin Rheumatol; 2024 Jan; 43(1):241-249. PubMed ID: 37787903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis.
    Siebert S; Behrens F; Lubrano E; Martin N; Sharaf M; Contré C; Theander E; Queiro R; Zimmermann M; Gossec L
    Rheumatol Ther; 2023 Apr; 10(2):489-505. PubMed ID: 36585602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: results from a real-life multicentre cohort.
    Ruscitti P; Pantano I; Cataldi G; Gentile M; Arrigoni F; Riccio L; Marrone S; Mauro D; Ursini F; Esposito M; Barile A; Fargnoli MC; Giacomelli R; Ciccia F; Cipriani P
    Rheumatology (Oxford); 2024 Apr; ():. PubMed ID: 38598432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group.
    Rocamora V; Crespi L; Ferran M; Llamas-Velasco M; Del Alcázar E; Carrascosa JM; Beltran E; Urruticoechea-Arana A; Estebaranz JLL; Vidal D; Riera J; Rodríguez L; Armesto S; Fernández JM; Aparicio G; Pérez S; Porcar S; Montesinos E; Gallardo F
    Dermatol Ther; 2022 Nov; 35(11):e15865. PubMed ID: 36175141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study.
    Bellis E; Ruscitti P; Donzella D; Crepaldi G; Data V; Gammino M; Gatto M; Guardo V; Lomater C; Marucco E; Saracco M; Iagnocco A
    J Pers Med; 2024 Jul; 14(7):. PubMed ID: 39063970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Ogdie A; Tesser J; Shiff NJ; Lin I; Chakravarty SD; Kelleman M; Dodge R; McLean RR; Broadwell A; Kavanaugh A; Merola JF
    Rheumatol Ther; 2023 Dec; 10(6):1479-1501. PubMed ID: 37597159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
    Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Ogdie A; Chakravarty SD; Shiff NJ; Lin I; McLean RR; Malley W; Spitzer RL; Kavanaugh A; Merola JF
    Drugs Real World Outcomes; 2022 Dec; 9(4):617-628. PubMed ID: 36243860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life efficacy of guselkumab in patients with early psoriatic arthritis.
    Pantano I; Mauro D; Romano F; Gambardella A; Valenti M; Simone D; Iacono D; Costanzo A; Argenziano G; Ciccia F
    Rheumatology (Oxford); 2022 Mar; 61(3):1217-1221. PubMed ID: 34152379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
    Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study.
    Mease PJ; Baraliakos X; Chandran V; Soriano ER; Nash P; Deodhar A; Rampakakis E; Shiff NJ; Chakravarty SD; Shawi M; Merola JF; McInnes IB
    ACR Open Rheumatol; 2024 Oct; ():. PubMed ID: 39365294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
    Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
    Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis.
    Campochiaro C; Tomelleri A; Sartorelli S; Cavalli G; De Luca G; Baldissera E; Dagna L
    Semin Arthritis Rheum; 2020 Jun; 50(3):509-514. PubMed ID: 32088012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
    Gottlieb AB; McInnes IB; Rahman P; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; Lavie F; Mease PJ
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36828643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
    Simon D; Kleyer A; Bayat S; Tascilar K; Kampylafka E; Meinderink T; Schuster L; Petrov R; Liphardt AM; Rech J; Schett G; Hueber AJ
    Arthritis Res Ther; 2019 Jul; 21(1):162. PubMed ID: 31269973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
    Coates LC; Gossec L; Zimmermann M; Shawi M; Rampakakis E; Shiff NJ; Kollmeier AP; Xu XL; Nash P; Mease PJ; Helliwell PS
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38531621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
    Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
    Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.